KRAS and lung adenocarcinoma: The patient did not harbor any activating mutation of EGFR, KRAS, or ALK genes; he was diagnosed as poorly differentiated lung adenocarcinoma stage 2B at the age of 51 and was a light smoker that used one pack per year.